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Disruption of mouse ERCC1 results in a novel repair syndrome
with growth failure, nuclear abnormalities and senescence
G. Weeda*, I. Donker*, J. de Wit*, H. Morreau†, R. Janssens*, C.J. Vissers‡, 
A. Nigg‡, H. van Steeg§, D. Bootsma* and J.H.J. Hoeijmakers*
Background: The structure-specific ERCC1/XPF endonuclease complex that
contains the ERCC1 and XPF subunits is implicated in the repair of two distinct
types of lesions in DNA: nucleotide excision repair (NER) for ultraviolet-induced
lesions and bulky chemical adducts; and recombination repair of the very
genotoxic interstrand cross-links. 
Results: Here, we present a detailed analysis of two types of mice with
mutations in ERCC1, one in which the gene is ‘knocked out’, and one in which
the encoded protein contains a seven amino-acid carboxy-terminal truncation. In
addition to the previously reported symptoms of severe runting, abnormalities of
liver nuclei and greatly reduced lifespan (which appeared less severe in the
truncation mutant), both types of ERCC1-mutant mouse exhibited an absence
of subcutaneous fat, early onset of ferritin deposition in the spleen, kidney
malfunction, gross abnormalities of ploidy and cytoplasmic invaginations in
nuclei of liver and kidney, and compromised NER and cross-link repair. We also
found that heterozygosity for ERCC1 mutations did not appear to provide a
selective advantage for chemically induced tumorigenesis. An important clue to
the cause of the very severe ERCC1-mutant phenotypes is our finding that
ERCC1-mutant cells undergo premature replicative senescence, unlike cells
from mice with a defect only in NER. 
Conclusions: Our results strongly suggest that the accumulation in ERCC1-
mutant mice of endogenously generated DNA interstrand cross-links, which are
normally repaired by ERCC1-dependent recombination repair, underlies both
the early onset of cell cycle arrest and polyploidy in the liver and kidney. Thus,
our work provides an insight into the molecular basis of ageing and highlights
the role of ERCC1 and interstrand DNA cross-links.
Background 
The nucleotide excision repair (NER) process recognizes
and eliminates a very broad spectrum of structurally
diverse DNA lesions [1]. The consequences of inborn
defects in NER are apparent from the rare human auto-
somal recessive syndrome xeroderma pigmentosum (XP),
characterized by ultraviolet light (UV) sensitivity to the
sun, pigmentation abnormalities, strong predisposition to
skin cancer in exposed areas, and frequently accelerated
neurodegeneration. Two other distinct NER disorders
have been recognized in humans: the severe neuro-
developmental conditions Cockayne syndrome (CS) and
trichothiodystrophy (TTD) (for a review see [2] and refer-
ences therein). In remarkable contrast to XP, neither CS
nor TTD is apparently associated with a clear predisposi-
tion to skin cancer. These three NER syndromes are
genetically heterogeneous and comprise at least ten com-
plementation groups: seven in XP (XP-A to XP-G), two in
CS (CS-A and CS-B) and three in TTD (TTD-A, and two
that are simultaneously XP groups: XP-B and XP-D) [3].
In addition to the human NER disorders, there is a second
type of mammalian NER mutant: UV-sensitive rodent cell
lines (complementation groups 1–11, which can be cor-
rected by human ERCC genes). The ERCC1 gene corrects
the repair defects of group 1 mutants, which are (like other
NER mutants) sensitive to UV, but which alone with
group 4 mutants are additionally very sensitive to DNA
cross-linking agents [4]. ERCC1 is not implicated in any of
the known XP, CS or TTD complementation groups [5].
The NER process entails damage recognition followed by
a ‘cut-and-paste’ mechanism involving a large number of
proteins [3,6]. The ERCC1 product was recently found to
reside with the XPF protein (also known as ERCC4) in a
complex which constitutes a structure-specific endonucle-
ase responsible for the incision in the damaged strand 5′ of
the lesion [7,8]. The first 214 amino acids of the ERCC1
protein are significantly homologous to the yeast NER
factor RAD10 [9], which is complexed with RAD1, the
yeast homologue of XPF [10,11]. Importantly, both yeast
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homologues are involved in two processes: NER and a
mitotic recombination pathway [12]. This explains the
sensitivity of ERCC1 and ERCC4 mutants to DNA cross-
links, which require mitotic recombination for their repair.
The remaining carboxy-terminal 80 amino acids of
ERCC1, which are not similar to RAD10, share clear
homology with the carboxyl terminus of the Escherichia coli
NER endonuclease UvrC [13], and are also similar to
numerous other nucleases [14]. Consistent with an antici-
pated nuclease-related function of this domain, our pre-
vious mutational analysis of ERCC1 has revealed that
deletion of the last four amino acids mildly affects NER
and cross-link repair, but that truncation of five or six
residues severely impairs both repair functions [14]. In
contrast, deletion of the less conserved first 91 residues
has no significant effect on its function. 
A severe ERCC1 mouse mutant, which displayed disturbed
growth, reduced life span and abnormalities of liver nuclei,
was described previously by McWhir and collaborators
[15]. In our study, we have generated two types of mouse
mutated at ERCC1: one in which the gene is ‘knocked out’
and one in which it is partially inactivated by introducing,
into the encoded protein, a carboxy-terminal truncation
that starts immediately after the carboxy-terminal UvrC-
homologous region. We have previously shown that this
seven amino-acid truncation includes two amino acids of
the domain found to be important for ERCC1 function as
determined in vitro, but does not cause dramatic protein
instability [14]. In addition to the features of ERCC1-
mutant mice described by McWhir and coworkers [15], we
provide evidence for spleen, kidney and cutaneous deficits,
and also a detailed analysis of NER, cross-link repair, cell
cycle arrest and replicative senescence. Importantly, our
results suggest that the accumulation of endogenous cross-
links as a result of ERCC1 inactivation leads to genomic
instability and significantly contributes to ageing in mice. 
Results
Targeting of the ERCC1 gene in embryonic stem cells
The minimal size of the functional ERCC1 protein that
we have previously deduced from in vitro deletion analysis
[14] is depicted schematically in Figure 1a. The targeting
constructs used for knockout and partial inactivation of
the gene and the various probes used for screening and
verification of the homologous recombination are outlined
in Figures 1b and 2b. The knockout vector consisted of an
approximately 9.5 kb isogenic mouse genomic HindIII/SalI
DNA fragment, in which a pMC1–neo cassette [16] inter-
rupts exon 7, thus aborting the essential carboxy-terminal
74 amino acids (Fig. 1b). 
The design of a construct for a more subtle mutation, trun-
cating the protein close to the end of the essential region,
was complicated. The human and mouse ERCC1 loci
contain another gene of unknown function which overlaps
the last exon of ERCC1 in the antisense direction ([17] and
data not shown). In order to avoid interference with this
function, we inserted the neo marker into the last intron of
ERCC1. This strategy gave the additional advantage that
ERCC1 transcription and mRNA processing would remain
intact and that the neo resistance gene would be removed
by splicing. The replacement-type vector also introduced a
premature stop codon at position 292 of mouse ERCC1,
removing the last seven amino acids (note that the mouse
ERCC1 protein has one residue more than human
ERCC1). Thus, the encoded protein (ERCC1*292) termi-
nates immediately after the UvrC-homologous region
(Figs 1a,2a). Our previously reported ERCC1 mutational
analysis indicated, however, that the truncation removes
just two amino acids of the ERCC1 essential domain, but
should not dramatically decrease protein stability [14].
Targeting of both constructs was evaluated by Southern
blot analysis using unique probes that hybridize outside
the targeting constructs (Figs 1c,2c). The frequency of
homologous recombination for the knockout and
ERCC1*292 constructs was approximately 5% (8 of 170
G418-resistant transformants) and 13% (23 of the 172
clones analyzed), respectively. In the case of the
ERCC1*292 mutation, two of the independent embryonic
stem (ES) cell clones were also analyzed by reverse-tran-
scriptase-coupled polymerase chain reaction (RT-PCR),
using ERCC1-specific cDNA primers and DNA sequenc-
ing to verify the presence of the mutation and to ensure
that the rest of the coding region, which was part of the
targeting construct, was still intact after the process of
homologous recombination.
Generation of ERCC1-mutant mice and analysis of ERCC1
expression
F2 offspring from each of two independent ERCC1 knock-
out and ERCC1*292 ES cell clones were born, and expres-
sion of the targeted gene was analyzed at the mRNA level
in mouse embryonic fibroblasts (MEFs), using RT-PCR
and dot-blot analysis (Fig. 3). Filters were hybridized with
wild-type or mutant-specific 32P-labelled oligonucleotides,
which distinguished ERCC1*292 transcripts from wild-type.
PCR products from fibroblasts of F2 offspring of the
ERCC1-knockout ES cell clones hybridized only to the
wild-type-specific primer if the offspring were wild-type
homozygous or heterozygous, whereas no mRNA could be
detected in homozygous mutant MEFs. RNA from het-
erozygous ERCC1*292 MEFs clearly hybridized to both
probes; in homozygous mutant ERCC1*292 MEFs, only
mutant transcript could be detected. We conclude that the
knockout allele is transcriptionally inactivated and that the
ERCC1*292 allele is still transcribed and, as shown by
sequence analysis (data not shown), is properly processed.
In order to determine the relative levels of ERCC1*292
message more accurately, RT-PCR products (from
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ERCC1*292 ES cells) were subcloned. Dot-blot analysis
revealed that, in 9 out of 70 recombinant clones, the
desired mutation could be detected (data not shown),
indicating that the transcript level from the ERCC1*292
allele is reduced to about 15% of the level of the non-tar-
geted allele. In an attempt to confirm the observation that
there was detectable ERCC1 transcript in the ERCC1*292
mice, we tested tissue extracts from ERCC1*292 mice and
their wild-type litter-mates using ERCC1-specific anti-
bodies; however, all the available antibodies, which were
raised against the human ERCC1 protein, did not recog-
nize the mouse protein. To test for expression of the anti-
sense gene at the ERCC1 locus, northern blot analysis of
kidney and liver RNA was performed; a probe correspond-
ing to the mouse genomic ERCC1 3′ region (probe C; see
Fig. 1b) that hybridizes to the antisense mRNA revealed a
transcript of 5–6 kb that was expressed in tissues of wild-
type, ERCC1*292 and ERCC1 knockout mice (data not
shown), indicating that gene targeting did not alter the
expression level of the antisense transcript. 
Phenotype, frequency of recovery, and pathology of
ERCC1-mutant mice
In order to investigate the effects of genetic background
on embryonic lethality and life span, in addition to the
C57Bl/6/129 hybrid ERCC1 knockout and ERCC1*292
mice, whose generation we have described, we also gener-
ated FVB/129 hybrid ERCC1*292 mice. A number of the
characteristics of ERCC1 deficiency have been described
by McWhir et al. [15], and are confirmed in both our
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Figure 1
Disruption of the ERCC1 gene: the knockout
construct. (a) The mouse ERCC1 protein,
showing regions homologous to yeast RAD10
and E. coli UvrC (in white), the minimal
functional region (in black), and the positions
of the neomycin insertion in the knockout (*)
and of the subtle mutation in the partial
inactivation mutant (*292). (b) Strategy for
inactivation of the ERCC1 gene by
homologous recombination in embryonic stem
(ES) cells. Part of the genomic structure of
the wild-type and mutated ERCC1 gene is
depicted, showing BamHI (B), ClaI (C),
HindIII (H), KpnI (K), and SalI (S) restriction
sites. Exons are numbered and indicated by
black bars above the line. Black boxes below
the line denote the DNA probes A, B and C
used for Southern blot analysis. The neo
cassette containing a diagnostic BamHI
restriction site was inserted into a ClaI site
that was generated by site-directed
mutagenesis in exon 7; the small arrows mark
the direction of neo transcription. Probe A
detects a 4.2 kb and an 8 or 8.5 kb BamHI
fragment (due to polymorphic differences
between 129 and C57Bl/6 DNA) in the
mutant and wild-type alleles, respectively.
Probe B covers the coding region of the
dominant selectable marker neo. Probe C
hybridizes to a 5 kb and an 8 or 8.5 kb BamHI
fragment in the mutant and wild-type alleles,
respectively. (c–e) Southern blot analysis of
BamHI-digested genomic DNA from an ES
cell clone (ES 1.14) and tail DNA from litter-
mates — homozygous wild-type (+/+),
heterozygous (+/–) and homozygous mutant
(–/–) — from an intercross of mice
heterozygous for ERCC1 knockout. As a
control, DNA from strains 129 and C57Bl/6
was included. Homologous recombination
was indicated by (c) probe A hybridizing to a
4.2 kb fragment, (d) probe B hybridizing to a
4.2 kb fragment and (e) probe C hybridizing to
a 5 kb fragment.
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ERCC1 knockout and ERCC1*292 mice. These include, for
all ERCC1-mutant mice, irrespective of genetic back-
ground, a frequency of recovery of homozygous mutants
far below Mendelian expectation (Table 1), a severely
runted phenotype (Fig. 4) and a markedly reduced life
span. Life span reduction was more severe in our ERCC1
knockout mice (C57Bl/6 background) and the FVB-back-
ground ERCC1*292 mice, which had maximal ages of
38 days and 78 days, respectively; C57Bl/6-background
ERCC1*292 mice had a life span of up to 6 months. The
ERCC1-mutant mice reported by McWhir et al. [15] died
between days 20 and 28. We also noted sex differences in
phenotype for the C57Bl/6-background ERCC1*292 mice:
male mice were more severely runted (only 25% of the
weights of controls, compared with 30–50% for females)
and had a shorter life span (data not shown).
We investigated when lethality (embryonic or post partum)
occurred and whether these features were influenced by
genetic background. Both ERCC1 knockout and
ERCC1*292 mice in a C57Bl/6/129 background revealed
early embryonal lethality (by day 13.5 after gestation;
Table 1), and growth delay was noted (data not shown).
Interestingly, embryonal lethality was not seen in
FVB/129-hybrid ERCC1*292 mice, although in this case
many ERCC1-mutant animals died at a later stage — the
same low frequency of homozygous mutant offspring was
found for all F1 crosses at the time of genotyping (10 days
post partum; Table 1). Together, our data suggest that, for
the ERCC1*292 mutation, the genetic make-up influences
the penetrance of ERCC1 deficiency. All further character-
izations were done in ERCC1*292 mice (and additionally in
ERCC1 knockouts where stated) in a C57Bl/6/129 hybrid
background.
Detailed histological examination was performed on a total
of 13 ERCC1*292 and ERCC1 knockout mice, sacrificed
when still in a good condition. We detected neither
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Figure 2
Disruption of the ERCC1 gene: the
ERCC1*292 mutation. (a) The nucleotide
sequence and encoded protein sequence (in
single-letter amino-acid code, with asterisks
indicating stop codons) of the 3′ end of wild-
type (wt) and mutant (m) murine ERCC1. An
introduced diagnostic BamHI restriction site
is boxed. (b) Strategy for introducing a stop
codon into exon 10 of ERCC1 by
homologous recombination in ES cells. Part of
the genomic structure of the ERCC1 locus is
depicted, annotated as for Figure 1b. The neo
cassette was inserted into a ClaI restriction
site that was generated by site-directed
mutagenesis in intron 9. The diagnostic
restriction site in exon 10 is indicated by an
asterisk. Probe A detects a 6.1 kb and an 8 or
8.5 kb BamHI fragment in the mutant and
wild-type alleles, respectively. Probe C
hybridizes to a 3.2 kb and an 8 or 8.5 kb
BamHI fragment in the mutant and wild-type
alleles, respectively. (c–e) Southern blot
analysis of BamHI digested genomic DNA
from ES clone 1.114 and 129 and C57Bl/6
mice, and tail DNA of the indicated
genotypes, probed with probes (c) A, (d) B
and (e) C. 
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pathological abnormalities in the heart, lung, brain and
eyes, nor any of the characteristics often found in XP
patients, such as neurological abnormalities, premalignant
lesions or immature sexual development (in mice up to
6 months old). By morphological criteria, the ovaries and
testes, although proportionately small, looked normal:
ovaries contained ova and follicles, sometimes with signs of
cyclic changes, indicating normal pituitary regulatory func-
tion, and spermatogenesis also appeared normal. ERCC1*292
mice that reached the age of approximately 6 months,
however, gave no progeny when mated with C57Bl/6 mice,
suggesting that they were infertile. Figure 5 shows the
histopathology of ERCC1*292 mice; identical results were
obtained with ERCC1 knockout mice (data not shown). 
Previously, McWhir et al. [15] reported light-microscopi-
cally detectable abnormalities in liver nuclei of ERCC1-
mutant mice. We observed similar nuclear abnormalities
(Fig. 5d), but in addition, the kidney, skin and spleen
were found to be abnormal. The skin of ERCC1*292 mice
was thin and lacked subcutaneous fat (Fig. 5a,b). In the
spleen of mutant mice at 3 weeks of age, an increased and
early onset of ferritin deposition was found (Fig. 5c),
which was absent from age-matched wild-type mice (data
not shown). The peripheral blood in some samples
showed an increase in Howel Jolly bodies (data not
shown). The increase in ferritin deposition might point to
an increased turnover of erythrocytes; however, there was
no sign of overt haemochromatosis. In the kidney, we
found dilated tubules containing leaked proteinaceous
material (Fig. 5e), indicative of renal dysfunction, as well
as nuclear abnormalities; these kidney abnormalities were
not seen in wild-type litter-mates (data not shown). 
Electron microscopy confirmed and extended the mutant-
specific nuclear abnormalities in liver and kidney (seen in
Fig. 5d,f and also McWhir et al. [15]): the chromatin was
very coarse, and the nucleoli were more prominent than
normal and showed an abnormal organization (Fig. 5g).
Furthermore, nuclear invagination and intranuclear inclu-
sions were observed (Fig. 5h). Flow cytometry of liver cells
of young ERCC1*292 mice showed increasing octaploidy
(Fig. 6a). The abnormal nuclear morphology was also
reflected in the distribution of nuclear size, as revealed by
nominal area measurements in liver sections (Fig. 6b).
Research Paper  Targeted disruption of ERCC1 in mice Weeda et al.    431
Figure 3
RT-PCR and dot-blot analysis of ERCC1 transcripts. Exons 9 and 10
of the mouse ERCC1 locus were amplified by RT-PCR (using total
MEF RNA from embryos on embryonic day 13.5 ). Amplified DNA from
homozygous wild-type (+/+), heterozygous (+/–) and homozygous
mutant (–/–) offspring of both ERCC1*292 (*292) and ERCC1
knockout (ko) F1 heterozygotes was dot-blotted and hybridized to
labelled oligonucleotide probes specific for (a) ERCC1*292 (p81) and
(b) wild-type ERCC1 (p228). (c) As a control, amplimers specific for
mouse XPB were added to the cDNA mix and amplified DNA was
hybridized to an XPB-specific oligonucleotide probe (p73). As a
control for the specificity of hybridization of the mutant and wild-type
ERCC1-specific oligonucleotides, both wild-type (wt-tc) and
ERCC1*292 (*292-tc) targeting constructs were also spotted.
(a)
(b)
(c)
+/+ +/– –/– +/+ +/– –/– wt-tc *292-tc
*292 ko
Figure 4
The ERCC1*292 mutation causes reduced growth. Homozygous wild-
type (back) and homozygous mutant (front) 3–4 week old litter-mates
(C57Bl/6/129 hybrid background) from a heterozygous ERCC1*292
intercross.
Table 1
Genotype of offspring and embryos derived from mice
heterozygous for mutations in ERCC1.
Mutation Age +/+ +/– –/–‡
ERCC1*292* Newborn 121 (35%) 210 (61%) 13 (4%)
E13.5 17 (31.5%) 34 (63%) 3 (5.5%)
ERCC1*292† Newborn 25 (27%) 60 (65%) 7 (8%)
E13.5 19 (23%) 42 (51%) 21 (26%)
ERCC1 knockout* Newborn 32 (30%) 70 (63%) 8 (7%)
E13.5 9 (24%) 24 (63%) 5 (13%)
Both embryos (from embryonic day E13.5) and neonates (10 days
post partum) were genotyped by Southern blot analysis using probe A
(see Fig. 1b); the numbers and proportions of homozygous wild-type
(+/+), heterozygous (+/–) and homozygous mutant (–/–) mice are
shown. *C57Bl/6/129 hybrid background. †FVB/129 hybrid
background. ‡All –/– mice and embryos of both genotypes displayed
severe growth retardation.
In order to find out whether excess programmed cell death
was involved in the growth deficit associated with ERCC1
mutation, serial-sectioned liver, kidney and spleen tissue
were analyzed using the TUNEL assay [18]. No clear
increase in TUNEL-positive nuclei was seen in the organs
from ERCC1-mutant mice compared to those from wild-
type litter-mates (data not shown). These results indicate
that excessive apoptosis did not occur in ERCC1-mutant
mice and suggest that the reduced size of these mice was
due to either a reduction or an early halt to proliferation.
Growth and cell cycle properties of ERCC1-mutant
fibroblasts
Because the reduced size of ERCC1-mutant mice sug-
gested a potential role for ERCC1 in cell proliferation, we
measured growth rates of primary ERCC1*292 MEFs in
vitro. Early-passage (passage 3) ERCC1-mutant MEFs
grew about three times as slowly as wild-type fibroblasts;
heterozygous MEFs had a doubling time of 36 hours com-
pared with 24 hours for wild-type fibroblasts (Fig. 7a). Pro-
liferation decreased with passage in culture and, by
passage 6–7, fibroblasts from ERCC1*292 mice failed to
divide, whereas MEFs from heterozygous and wild-type
litter-mates grew quite rapidly (three independent cell
lines of each genotype were tested). The homozygous
mutant MEFs were larger than wild-type cells and con-
tained giant polyploid nuclei (compare Fig. 7a and 7b). All
MEFs showed contact inhibition, but monolayers of wild-
type cells were more dense (1.45 × 105 cells per cm2) than
those of homozygous mutant MEFs (0.9 × 105 cells
per cm2). The reduced life span and rate of proliferation of
ERCC1-mutant primary cells indicate an early onset of cel-
lular replicative senescence in these cells. The difference
in doubling time was partly due to a decrease in the
number of dividing cells in ERCC1*292 cultures, as deter-
mined by incorporation of bromodeoxyuridine (BrdU) into
chromosomal DNA during a 48 hour labelling period.
Only 53% of passage 3 ERCC1*292 MEFs were actively
cycling, compared with 91% of controls. 
In order to analyze cell cycle properties, we pulse-labelled
cells with BrdU for 1 hour, and followed their progression
through the cell cycle. In the cycling population (which
was close to 50% for ERCC1*292 fibroblasts), the relative
distribution of cells in the different cell cycle phases was
similar for ERCC1*292 cells and wild-type controls (Fig. 7c,
curves with solid lines, –MMC). This indicates that cycling
ERCC1-mutant MEFs do not accumulate at a specific
stage of the cell cycle. Consistent with the finding that
many ERCC1-mutant cells do not cycle, we find increased
levels of p21cip1/waf1 in ERCC1-mutant MEFs compared
with wild type controls (by immunoblotting; data not
shown). In order to examine whether untransformed
ERCC1*292 MEFs exhibit a cell cycle arrest in response to
DNA damage, the effect of treatment of ERCC1*292 MEFs
with DNA-damaging agents was investigated. Following
treatment with a low dose of the cross-linking agent
mitomycin C (MMC), homozygous mutant MEFs, but not
wild-type (repair-proficient) MEFs, exhibited a DNA-
damage-induced delay in G2 (Fig. 7c, dashed lines,
+MMC), consistent with ERCC1-mutant MEFs having
both a cross-link repair defect and a normal G2 cell cycle
arrest mechanism. Cytogenetic analysis of ERCC1-mutant
MEFs revealed a normal karyotype and no detectable
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Figure 5
Histopathology of offspring of ERCC1*292 F1 heterozygotes at
3 weeks of age. Sections of the skin (18× magnification) of (a)
homozygous wild-type and (b) homozygous mutant mice; note the
absence of subcutaneous fat (indicated with asterisks) in homozygous
mutant mice. (c) Section of the spleen (18× magnification) of a
homozygous mutant mouse; note the ferritin staining (blue) in
macrophages. (d) Liver section (haematoxylin-stained and eosin-
stained; 270× magnification) of a homozygous mutant mouse showing
anisokaryosis. Several aberrantly enlarged nuclei are indicated with
arrowheads. (e) Kidney sections (haematoxylin-stained and eosin-
stained; 66× magnification) of a homozygous mutant mouse showing
dilated tubules occupied with leaked eosinophilic proteinaceous
material (indicated with arrowheads). (f) Higher power view of a kidney
section (270× magnification) showing aberrant nuclei (indicated with
arrowheads). Electron-microscopical analysis of (g) kidney and (h) liver
sections of a homozygous mutant mouse showing that the chromatin is
very coarse. Nuclear inclusions are indicated with an asterisk: some
inclusions are associated with nucleoli (see asterisk in (g)).
increase of chromosomal breaks, gaps and abberations
compared with wild-type controls (data not shown).
DNA repair parameters of ERCC1-mutant fibroblasts
McWhir et al. [15] reported increased UV sensitivity and
reduced incision and dimer removal after UV exposure for
cells derived from their ERCC1-deficient mouse mutant. In
order to extend these findings, we analyzed DNA repair
and incision using an assay for UV-induced unscheduled
DNA synthesis (UDS) of primary MEFs (three indepen-
dent cell lines from each genotype). UDS in ERCC1*292
cells was extremely low (4% of that of wild-type cells; Fig.
8). Interestingly, fibroblasts from heterozygous litter-mates
showed a slight, but significant, reduction in UDS (to a
level of 73% that of wild-type controls). Similar results were
obtained with ERCC1 knockout cells (data not shown). 
As an estimate of another repair parameter, we measured
cell survival after exposure to various genotoxic agents. In
addition to the UV sensitivity (Fig. 9a) we investigated
sensitivity to DNA cross-linking agents. A hallmark of
chinese hamster ovary cell lines that contain mutations in
ERCC1 (or ERCC4) is their extreme sensitivity (80–100-
fold above controls) to cross-linking agents, presumably
Research Paper  Targeted disruption of ERCC1 in mice Weeda et al.    433
Figure 6
(a) Liver cells from homozygous wild-type
(+/+), heterozygous (+/–) and homozygous
mutant (–/–) offspring (17–20 days old) of
ERCC1*292 F1 heterozygotes were isolated
and the DNA content was determined by flow
cytometry after DNA staining with propidium
iodine. The positions of peaks for 2N, 4N and
8N DNA content are shown on the
histograms. (b) Morphometric analysis of
ERCC1*292 liver nuclei. Histograms show the
nominal areas of nuclei for a wild-type and
homozygous mutant animal, illustrating the
range of enlarged nuclei.
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Figure 7
(a) Growth kinetics of primary fibroblasts.
Passage-3 MEFs (105) from wild-type (+/+),
heterozygous (+/–) and homozygous mutant
(–/–) offspring of ERCC1*292 F1
heterozygotes were plated in 60 mm culture
dishes. Doubling times were calculated from
the exponential portion of the curve to be
approximately 24 h, 36 h and 73 h for +/+, +/–
and –/– MEFs, respectively. (b) Microscopical
analysis (phase contrast; magnification 16×) of
MEFs from ERCC1*292 mice and wild-type
litter-mate controls. Wild-type MEFs reached a
two-fold higher saturation density compared
with ERCC1-mutant fibroblasts. Arrowheads
point to giant nuclei. (c) Cell cycle progression
of S phase wild-type and ERCC1*292 MEFs
after a 1 h pulse with bromodeoxyuridine
(BrdU) and with and without treatment with
0.4 mg ml–1 mitomycin C (MMC). The
percentage of G1, S and G2/M phase cells
among the cycling population (BrdU-positive)
was quantified and is presented in the form of
area plots, in which the percentages of cells in
each cell cycle phase are plotted against time.
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reflecting the role of the ERCC1 complex in recombina-
tional repair. As shown in Figure 9b, most ERCC1-mutant
MEFs displayed a clear sensitivity to MMC, but a small
fraction seemed resistant to MMC concentrations over a
wide range. Comparable survival curves were obtained
when another cross-linking agent, cisplatin, was used
(data not shown), ruling out the possibility of a defect in
drug metabolism. Moreover, when we examined the sur-
vival of the ERCC1-mutant MEFs after treatment with
7,12-dimethylbenz[a]anthracene (DMBA), a chemical
agent that causes only bulky adducts, which are substrates
for NER, a profound sensitivity was found (Fig. 9c) that
was in the same range as that for XPA–/– cells [19]. No
resistant cell population was apparent, however, indi-
cating that the resistance is specific to the removal of
cross-linking lesions, which are largely eliminated by
recombinational repair. 
A possible explanation for the ERCC1-mutant cell popula-
tion resistant to DNA cross-linking is the existence of
another recombination repair process (for example, homol-
ogy-dependent recombination repair) active only at a spe-
cific stage of the cell cycle and requiring cell cycle arrest.
As shown in Figure 7c, the mechanism of damage-induced
G2 cell cycle arrest is still functional in the ERCC1-mutant
MEFs. Unfortunately, the limited lifespan of the primary
MEFs precluded retesting of the resistant cell fraction for
MMC sensitivity. A similar bimodal behaviour was found,
however, for some chinese hamster ovary NER mutants:
in this case, the resistant fraction showed the same sur-
vival as the original cell population (data not shown), con-
sistent with the explanations given above. Transfection of
immortalized mouse ERCC1*292 fibroblasts with wild-type
human ERCC1 cDNA fully complemented the UV sensi-
tivity (Fig. 9d), indicating that the repair defect is the
434 Current Biology, Vol 7 No 6
Figure 8
P
ro
po
rt
io
n 
of
 c
el
ls
 (%
)
100
80
60
40
20
0
26.9 –  0.6 (100%) 19.7 –  0.5 (73%) 1.2 –  0.1 (4%)
Number of grains per nuclear squareNumber of grains per nuclear squareNumber of grains per nuclear square
+/+ +/– –/–
6 12 18 24 30 36 42 6 12 18 24 30 36 42 6 12 18 24 30 36 42
DNA repair capacity of MEFs from homozygous wild-type (+/+), heterozygous (+/–) and homozygous mutant (–/–) offspring of ERCC1*292 F1
heterozygotes. Histograms of UDS are shown, indicating the average UDS as a value and as a percentage of the wild-type control value. 
Figure 9
0 1 2 3 40 5 10 15 20
0.01 0.1
10
1
10
100 100
0.1
1
1 2 4 8 0.1 0.2 0.4 0.8
00
11
1010
100100(a) (c)(b) (d)
C
el
l s
ur
vi
va
l (
%
)
C
el
l s
ur
vi
va
l (
%
)
C
el
l s
ur
vi
va
l (
%
)
C
el
l s
ur
vi
va
l (
%
)
UV (J m–2) [DMBA] (µg ml–1)[MMC] (µg ml–1) UV (J m–2)
ko +/+
ko +/–
ko –/–
*292 +/+
*292 +/–
*292 –/–
ko +/+
ko +/–
ko –/–
*292 +/+
*292 +/–
*292 –/–
*292 +/+
*292 –/–
VH25
XP25RO
*292 +/+
*292 –/–
*292 –/– + pEF1αE1
*292 –/– + pCMVE1
Cell survival of primary MEFs derived from offspring of ERCC1*292
(*292) and ERCC1 knockout (ko) F1 heterozygotes after exposure to
genotoxic agents. Survival of homozygous wild-type (+/+),
heterozygous (+/–) and homozygous mutant (–/–) cells after exposure
to (a) UV and (b) a 1 h pulse of MMC. Each value is the mean of the
survivals of three independent MEF cell lines, tested in duplicate. (c)
Survival of cells from ERCC1*292 mutant mice and wild-type litter-
mates after exposure to 7,12-dimethylbenz[a]anthracene (DMBA). The
normal human fibroblasts VH25 and the human XP cell line, XP25RO
(XP-A complementation group), were included as controls. The DMBA
survival of XPA–/– MEFs is identical to that of XP25RO cells
(unpublished observations). (d) Survival, following UV exposure, of
ERCC1-mutant MEFs transfected with the human ERCC1 minigene
constructs pEF1aE1 and pCMVE1, which contain wild-type human
ERCC1 cDNA driven by the human elongation factor-1a and CMV
promoters, respectively. Points are average values for duplicate wells
(± SEM).
result of ERCC1 targeting. From this set of experiments,
we conclude that both the ERCC1 knockout and
ERCC1*292 mice have a severe NER defect and a defi-
ciency in cross-link repair. 
Carcinogenicity studies
In order to establish whether the ERCC1*292 mice are sus-
ceptible to developing skin cancer, four three-week-old
mutant mice were exposed to 30 mg DMBA, followed by a
promotion protocol (2.5 mg TPA administration twice a
week). As a control, both heterozygous and wild-type
litter-mates (20 of each) were divided into four groups,
each receiving 0, 5, 15 or 30 mg DMBA, followed by the
TPA treatment. The dose given to ERCC1-mutant mice
was chosen because XPA–/– mice, which are also totally
NER-deficient, treated with the same dose showed only
reversible skin abnormalities (Fig. 10d). However, treated
ERCC1-mutant mice displayed massive epidermal necro-
sis and minimal infiltration of leucocytes (Fig. 10c). All
ERCC1-mutant mice died three days after the first admin-
istration of DMBA, whereas XPA–/– mice appeared normal
(both strains are in the same 129/C57Bl/6 hybrid genetic
background). These data indicate that ERCC1-mutant
mice are much more sensitive to DMBA than are XPA–/–
mice, which is in contrast to the corresponding MEFs,
which are equally DMBA-sensitive (Fig. 9c). Importantly,
mice heterozygous for the ERCC1*292 allele did also not
display increased DMBA sensitivity, nor (36 weeks after
the start of the DMBA-treatment) a clear cancer predis-
position (data not shown). Both homozygous wild-type
(28/63) and heterozygous (23/63) DMBA-treated mice
developed one or more papillomas. Tumour DNA of het-
erozygotes was analyzed by Southern blotting, but there
was no evidence for loss of heterozygosity of the wild-type
ERCC1 allele (data not shown), indicating that loss of the
remaining functional allele — and thereby inactivation of
the two DNA repair pathways — does not provide a selec-
tive advantage for tumour development. 
Discussion
Comparison of the ERCC1 knockout and ERCC1*292 alleles
at the molecular and phenotypical level
Besides its involvement in NER, the ERCC1–XPF
endonuclease is also implicated in the repair of cross-
links, most likely via a mitotic recombination repair
pathway. Consequently, a defect in this gene is expected
to cause a combination of features derived from deficien-
cies in both systems. Our previous mutational analysis of
ERCC1 has shown that many of the alterations to the
middle part of the protein render it unstable, presumably
by impairment of the stabilizing interaction with XPF
[14]. On the other hand, deletion of five or six carboxy-
terminal amino acids affects both ERCC1 repair functions
but does not dramatically destabilize the protein [14]. In
addition, we found that a low level of ERCC1–XPF may
be sufficient for the repair of very genotoxic DNA cross-
links, but not for NER [14]. In view of the dual function
of the protein and the notion that its total inactivation
results in a very severe phenotype [15], we decided to
generate two types of ERCC1-mutant mouse model: an
ERCC1 knockout mouse, and one in which the ERCC1
protein contained a seven amino acid carboxy-terminal
truncation (equivalent to deleting six residues of the
human protein). In RT-PCR experiments using ERCC1
knockout MEFs, no ERCC1 mRNA could be detected.
This excludes the possibility of dominant-negative effects
of a truncated ERCC1 protein and indicates that the
knockouts represent true null mutants. In contrast, RNA
expression was detected for the ERCC1*292 allele, but the
level of transcript was only about 15% of the expected
level, probably as a consequence of the marker insertion
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Figure 10
Acute effects in the skin of ERCC1*292 and XPA–/– mice after
treatment with DMBA. Shaved mice (3 weeks of age) were treated
with a single dose of 30 mg DMBA. Three days after treatment, part of
either the exposed skin or untreated skin from dead ERCC1*292-
mutant mice or sacrificed control animals was sampled and processed
for histopathology; skin is shown at 270× magnification. (a) Untreated
skin from wild-type litter-mates of ERCC1*292 mice. The effects of
DMBA treatment on (b) wild-type litter-mates of ERCC1*292 mice and
(c) ERCC1*292 mice. Hardly any epidermal changes are detectable for
wild-type mice: a minimal influx of inflammatory cells is noted
(indicated with an asterisk), as are signs of parakeratosis (indicated
with an arrow). In treated ERCC1*292 mice, the dermal as well as
epidermal changes are severe and characterized by massive necrosis
of epidermis and papillary dermis, and a minimal influx of inflammatory
cells in the dermis and epidermis. (d) Treated skin from XPA–/– mice.
Dermal as well as epidermal changes are noticeable and
characterized by epidermal degeneration, necrosis and pustule
formation (indicated with an arrow) and a marked influx of inflammatory
cells in dermis and epidermis.
and/or the mutation. MEFs heterozygous for ERCC1*292
revealed a small but significant reduction (27%) in UV-
induced UDS (Fig. 8). Independently, McWhir et al. [15]
reported a similar decrease in the level of incision and an
accumulation of DNA breaks in MEFs heterozygous for a
mutation in ERCC1. These findings point to haplo-insuffi-
ciency — the normal NER capacity is diminished when
there is only one functional ERCC1 allele. This suggests
that, under normal conditions, ERCC1 is a rate-limiting
factor in NER of MEFs. 
Both at the cellular level and at the level of the organism,
the ERCC1 knockout and ERCC1*292 phenotypes are very
alike and each mutation has a dramatic effect on NER. In
view of the anticipated partial stability of the ERCC1*292
protein, and the fact that it still harboured the intact UvrC-
homologous domain, the ERCC1*292 mice might have dis-
played a partial defect in cross-link repair. This was not
found, however. Therefore, protein truncation as well as
reduced transcript levels may have made the ERCC1*292
phenotype more severe than anticipated. The major
phenotypic difference between the ERCC1 knockout and
ERCC1*292-mutant mice, however, seemed to be in the life
span. The ERCC1 knockout mice all died before day 38,
whereas the maximum life span of ERCC1*292 mutants was
considerably longer (6 months). All the ERCC1-mutant
mice described by McWhir and coworkers [15] died even
earlier than our knockout mutants, between days 20 and
28. Furthermore, we showed that both genetic background
and sex influenced the penetrance of embryonal and peri-
natal lethality and of lifespan alterations. 
Comparison with other NER-deficient mouse models and
genotype–phenotype correlations
The consequences for the mouse of a defect solely in
NER are apparent from the XPA knockout mouse. XPA–/–
mice are viable, develop normally and have a normal life
span, but are photosensitive and predisposed to UV-
induced skin cancer and ocular tumours [19,20]. XPA–/–
MEFs have a total NER deficiency and are hypersensitive
to UV and DMBA [19,20]. The effects of NER loss — con-
firmed by the phenotype of the XPC knockout mice,
which have a specific defect in the global genome repair
subpathway of NER [21,22] — are mild compared with the
effects of ERCC1*292. McWhir et al. [15] proposed accumu-
lation of an endogenously generated NER lesion as the
cause of the ERCC1-mutant features. As the NER defect
in XPA null and ERCC1 null mutants is the same, however,
this explanation has become unlikely. Instead, we infer
that in the ERCC1*292 mice, the extra pathological charac-
teristics, which lack a parallel in the human XP patients,
must be due to the additional ERCC1 function. Thus, the
liver, kidney and spleen manifestations, as well as the
developmental delay and reduced life span, are most prob-
ably derived from impairment of the interstrand cross-link
repair pathway. The same holds true at the cellular level
for the striking features of the ERCC1-mutant MEFs;
namely the nuclear abnormalities (including enlarged poly-
ploid nuclei and nuclear inclusions) and, importantly,
replicative senescence. 
How can we explain the ‘non NER’ clinical manifesta-
tions in terms of inactivation of ERCC1-dependent cross-
link repair? The liver and kidney malfunctions are
probably the consequence of the prominent nuclear
abnormalities seen in these organs. Polyploid nuclei nor-
mally develop later in life, but are already apparent at, or
soon after, birth in ERCC1-mutant mice. Other indications
also point to premature senescence, such as the occur-
rence of eosinophilic nuclear inclusions, which have fre-
quently been observed in cells of ageing animals [23]. In
addition, the striking early onset of a proliferative arrest of
ERCC1*292 MEFs (with a concomitant increase in
p21cip1/waf1), which is due to the presence of a large propor-
tion of cells arrested in the cell cycle, is a hallmark of
replicative senescence (see [24] for a recent overview).
The early stop in cellular proliferation may also explain
the severe reduction in weight, the poor and delayed
development, and early death. Thus, ERCC1-mutant mice
display several signs of premature senescence. What is the
relationship between premature senescence and impaired
cross-link repair? The involvement of defective cross-link
repair suggests that accumulation of interstrand cross-links
causes the observed phenomena. Candidates for endoge-
nous agents inducing such lesions are mutagenic carbonyl
compounds such as malondialdehyde (MDA), which is the
major by-product of arachidonic acid metabolism and lipid
peroxidation [25]. MDA produces adducts (mainly at
deoxyguanosine) and induces interstrand cross-links,
which have been detected in liver DNA, for example, and
have been implicated in carcinogenesis [25]. 
Persistent DNA damage triggers p53 accumulation, which
in turn induces cell cycle arrest, thereby providing a time-
window for DNA repair and the prevention of mutagen-
esis [26]. Moreover, p53 has been implicated in a spindle
checkpoint that controls the ploidy of cells [27]. One of
the most important downstream effectors induced by p53
is the cell cycle inhibitor p21cip1/waf1 [28], which has also
been associated with cell differentiation and senescence.
The involvement of p21cip1/waf1 in the ERCC1-dependent
cross-link repair pathway is strongly supported by the
striking resemblance of ERCC1*292 mice to transgenic
mice that express high levels of p21cip1/waf1 in the liver
[29]. These mice display dramatically inhibited hepato-
cyte proliferation, resulting in aberrant tissue organization,
runted liver and body growth and increased mortality; fur-
thermore, large polyploid nuclei were observed, also sug-
gesting arrest during the G2 phase of the cell cycle [29]. 
The body of evidence for the involvement of p21cip1/waf1
and p53 in ERCC1-dependent cross-link repair is
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compelling: first, as mentioned before, we find higher
levels of p21cip1/waf1 in untreated ERCC1*292 MEFs than in
wild-type controls; second, McWhir and coworkers [15]
have shown accumulation of p53 in liver, kidney and brain
of ERCC1-mutant mice; and third, under certain condi-
tions, p53 activation triggers apoptosis in response to
DNA damage [30], although overexpression of p21cip1/waf1
in liver cells does not lead to increased apoptosis [29].
Similarly, we failed to detect high levels of apoptosis in
either ERCC1-mutant mice or cultured ERCC1-mutant
MEFs (data not shown). In summary, our data, supported
by many independent findings, suggest that very geno-
toxic lesions, such as MDA-induced DNA cross-links,
which are normally targeted by the ERCC1-dependent
recombination pathway,  accumulate at a high rate in
ERCC1-mutant mice, and activate p53. In turn, p53
induces p21cip1/waf1, resulting in early cell cycle arrest,
nuclear polyploidy and other cellular abnormalities.
These features of premature senescence cause liver and
kidney malfunction, arrested development and early
death. Thus, endogenously generated cross-links may be
an important factor in the process of ageing, and ERCC1-
dependent recombination may constitute a critical barrier
against senescence.
ERCC1 and human repair syndromes
ERCC1 is one of the few NER genes for which no corre-
sponding human (repair) disorder is known. This may be
due to the severe consequences of ERCC1 inactivation,
which cause prenatal or early postnatal death. As in the
case of the XPF subunit of the ERCC1/XPF endonucle-
ase, a mutation affecting only the NER function, but
leaving sufficient amounts of complex for its role in cross-
link repair, is expected to give a phenotype very similar to
that of XP-F patients [7,14]. The XP-F complementation
group is characterized by relatively mild XP features, with
late onset of symptoms. Fibroblasts from XP-F patients
still perform a low level (15–20%) of DNA repair [31].
Apparently, the low concentration of the ERCC1–XPF
complex in these cells is rate-limiting for NER but still
permits some repair to occur. This concentration may be
sufficient to cope with a low steady-state DNA-damage
load. Moreover, for high UV doses, a low but long-lasting
type of repair activity has been observed in XP-F cells
[32]. In the end, this may still permit removal of a consid-
erable fraction of the lesions.
The phenotype of the ERCC1-mutant mice described
here may provide clues for a corresponding syndrome in
man resulting from a more severe impairment of ERCC1
function. In extrapolating to man, it should be kept in
mind that, except for the repair parameters, the genetic
background in mice already appears to have a significant
effect on the penetrance and expressivity of the clinical
features. With this caveat in mind, rare genetically hetero-
geneous, autosomal recessive disorders such as Roberts
syndrome may be considered potential candidates for an
ERCC1 defect. Roberts syndrome patients display a
variety of developmental anomalies, including renal
defects and malignancies. Interestingly, some patients
exhibit, at the cellular level, nuclear (heterochromatin)
abnormalities and UV sensitivity as well as cross-link sen-
sitivity [33]. In one Roberts syndrome patient, we failed to
find defects in ERCC1 at either the DNA or RNA level
(data not shown); however, this does not exclude ERCC1
mutations in other cases. Very recently, we have identified
an XP patient with a mutation assigned to the XPF com-
ponent of the dual functional ERCC1/XPF endonuclease
who has a number of unusual features including growth
defects and premature senescence, indicating the exis-
tence of further parallels between the mouse ERCC1-
mutant system and human syndromes (our unpublished
observations). A more versatile experimental animal
model for ERCC1 deficiencies, which might direct assign-
ment of the clinical parameters to the different ERCC1
activities, awaits the generation of mouse mutants with
specific defects in each of the ERCC1 functions.
Materials and methods 
Targeting constructs and disruption of ERCC1 in ES cells
Genomic ERCC1 fragments were obtained by screening a 129/CCE
EMBL4 genomic library (kindly provided by G. Grosveld) with a murine
ERCC1 cDNA [19]. A knockout targeting construct was prepared by
subcloning a ~9.5 kb HindIII/SalI fragment containing murine ERCC1
exons 6–10 into pBR322. A unique ClaI restriction site was generated
in exon 7 by uracil-DNA-mediated mutagenesis as described before
[34], using primer p89 (5′ TCCAGCTTATCGATAAGGAGGT). The
pMC1-neo resistance gene [16], containing a diagnostic BamHI
restriction site, was inserted into the unique ClaI site, yielding
pE1NEO7. The ERCC1*292 targeting construct was generated as
follows. A 2.8 kb KpnI/XbaI fragment containing ERCC1 murine
exons 7–10 was subcloned into pTZ19 (Pharmacia). Using site-
directed mutagenesis as described above, a stop codon was intro-
duced into mouse ERCC1 exon 10, deleting the amino-terminal
7 amino acids, using primer p81 (5′ GGCACTTTGAGGGATCC-
TATTCGTGTAGTACT). In addition, we introduced a unique ClaI
restriction site in intron 9, approximately 350 bp upstream of exon 10,
in order to insert the pMC1-neo resistance gene, using primer p82
(5′ TAGTACATCGATGGGCGG). All critical regions were confirmed
by double-stranded-DNA sequence analysis [35]. 
The targeting constructs were separated from vector sequences by gel
electrophoresis, purified by electroelution and introduced into 129/Ola-
derived ES cells by electroporation (E14 cells were kindly provided by
A. Berns and H. te Riele). Routinely, 1 × 107 cells were electroporated in
ES medium, supplemented with fetal calf serum (FCS) and containing
10–15 mg linearized targeting vector, at 585 V cm–1, 1200 mF, for
10 msec using a Progenetor II PG200 gene pulser (Hoeffer). Cells were
seeded onto gelatin-coated 10 cm dishes (106 cells per plate) and, after
24 h, subjected to neomycin selection (200 mg ml–1) in Dulbeccos’
modified Eagles medium (DMEM) containing 60% Buffalo rat liver con-
ditioned medium (BRL) [36] and supplemented with 10% FCS, 1%
non-essential amino acids, 0.1 mM 2-mercaptoethanol and LIF
(1000 units ml–1; Gibco). After 6–7 days, individual G418-resistant
clones were picked into 24-well dishes (Costar) and expanded (no
feeder layer). Half of the cells in the 24-well dish was expanded and
frozen at –80°C, and the other half was used to identify targeted events.
Chromosomal DNA was extracted from expanded cultures as described
previously [37], digested with BamHI, and analyzed by Southern blot
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analysis using probe A (a genomic 5′ ~0.3 kb HindIII fragment contain-
ing intron sequences flanking the targeting construct. Targeted clones
were reconfirmed using probe C (an internal 3′ ~1.2 kb XbaI/KpnI frag-
ment 3′ of the ERCC1 gene) and probe B (a probe covering the neo
coding region) (see Fig. 1). All homologous recombinants showed
bands diagnostic for correct integration of the neo marker without
random integration of additional copies of the targeting construct. In
case of the ERCC1*292 mutation, two independent ES clones were ana-
lyzed by RT-PCR. Mouse ERCC1 cDNA harbouring the ERCC1*292
mutation was subjected to RT-PCR using primers p141 (5′ TTGTTC-
AAGTGGATG) and p92 (5′ CTGGGCATGGAAAATTC) to amplify the
region covering the mouse ERCC1 gene that was part of the targeting
construct. The PCR fragment was subcloned into an M13mp18-cloning
vector and individual clones were analyzed by replica-plating using
mutant-specific p81 primer and wild-type-specific p228 primer
(5′ GGCACTTTGAGGAAGGGTTCGTGTAGTACT). Two ES cell lines
from each targeting experiment were used for blastocyst injection.
The complete 1.1 kb human ERCC1 cDNA fragment was inserted into
the pBluescript vector KS+ (Stratagene). A ~2.4 kb human elongation
factor-1a (EF1a) promoter fragment [38], including the first intron, was
inserted into the 5′-end of this construct. The 2.4 kb poly(A) fragment
of the human b-globin was inserted in the 3′-end of this construct,
yielding peF1aE1. The plasmid pCMVE1 is similar to peF1aE1, but
contains the CMV promoter instead of the EF1a promoter.
Generation of ERCC1-mutant mice and culturing of MEFs
Chimeric mice were obtained by injecting 10–15 ES cells of the two
different types of ERCC1-mutant clones into C57Bl/6 blastocysts. ES
cells were karyotyped before injection. An average of 8 blastocysts
was transferred into pseudopregnant female recipient BCBA mice.
Male chimeras were bred to C57Bl/6 animals to generate the ERCC1-
mutant mice described in this study. In addition, male chimeras were
also bred to FVB animals to investigate the effects of genetic back-
ground on embryonic lethality and lifespan. Targeted ES cell clones
produced male chimeras whose germline transmitted the agouti coat
colour marker in nearly all offspring. Homozygous ERCC1-mutant mice
were obtained by intercrossing F1 heterozygotes. Southern blot analy-
sis of tail DNA (using probe A; Fig. 1a) was used to genotype the off-
spring, using standard conditions. 
MEFs were isolated from day 12–13 embryos. Part of the embryo was
used for genotyping. The remaining embryonic tissue was minced
using a pair of scissors and immersed in a thin layer of F10/DMEM
culture medium supplemented with 10% FCS and antibiotics. After
24 h, 5 ml culture medium was added and after 4–5 days, the culture
was trypsinized and cultured up to passage 6–9. Spontaneous immor-
talized cell lines were obtained by continuous subculturing of primary
MEFs. DNA transfections of immortalized MEFs were performed using
lipofectin (Gibco). 
UDS, survival assays and in vivo DMBA treatment
For UDS testing, fibroblasts (passage 4–6) were seeded onto cover-
slips at day zero. The next day, cells were washed with phosphate-
buffered saline (PBS) and irradiated with 16 J m–2 UV-C (Philips, TUV
lamp). Subsequently, cells were incubated for 2.5 h in culture medium
containing 10 mCi ml–1 [3H]thymidine (50 Ci mmol–1; Amersham), fixed
and subjected to autoradiography as described before [39]. 
For survival assays, primary MEF cultures were exposed to UV or incu-
bated with MMC for 1 h and allowed to grow for another 4–5 days
before reaching confluency. Cells were labelled with [3H]thymidine as
described above, rinsed thoroughly with PBS and lysed in 0.2 M
NaOH. The number of proliferating cells in each dish was estimated by
scintillation counting of the radioactivity incorporated during a 3 h
pulse-labelling. Cell survival was expressed as the ratio of irradiated
over unirradiated cells. For DMBA treatment, cells were incubated with
DMBA-containing medium for 2 h on day one. To activate DMBA, a
microsomal S9-fraction (TNO-voeding, Zeist) was added. Cells were
washed twice and grown until day six. Cell survival was measured by
addition of the tetrazolium salt XTT (final concentration 0.12 mg ml–1)
to the culture medium. The amount of formazan dye formed after 2 h
incubation was measured using an enzyme-linked immunosorbent
assay reader, as described by the manufacturer (Boehringer). 
For the in vivo DMBA experiment, about four weeks after birth,
20 ERCC1+/+ and 20 ERCC1+/– mice were treated once a week on
the shaved back with 0, 5, 15 and 30 mg DMBA dissolved in 100 ml
acetone; ERCC1–/– mice (4) received only the 30 mg DMBA treatment.
After DMBA treatment, the mice received the phorbol ester TPA
(2.5 mg in 100 ml acetone) twice a week for twenty weeks. 
Histological studies and electron microscopical analysis
Before postmortem examination, all animals were sacrificed by cervical
dislocation. Tissues were fixed in 10% neutral buffered formalin. Follow-
ing appropriate fixation times, tissues were trimmed, dehydrated through
ascending grades of ethyl alcohol, cleared in xylene, and infiltrated with
paraffin wax. Tissue sections of 4 mm were prepared and stained with
haematoxylin and eosin. Ferritin staining was performed as described by
Simpson et al. [40]. Sections (4 mm) were cut and stained with haema-
toxylin and eosin and Perls’s for iron. For electron microscopy, liver and
kidney were fixed in a mixture of glutaraldehyde (1.5%) and para-
formaldehyde (1.5%) in phosphate buffer at pH 7.3. Organs were post-
fixed in 1% OsO4, 1.5% potassium hexanoferrate, rinsed in cacodylate
and 0.2 M sodium maleate buffers (pH 6.0), and block-stained with 1%
uranyl acetate. Following dehydration, tissues were embedded in Epon.
Flow cytometry and morphometric measurements
Replicative DNA synthesis and DNA content were analyzed using
bivariate flow cytometry according to established protocols [41]. Liver
cells were stained with propidium iodine and analyzed on a FACScan
cytometer using the Lysis II program (Becton-Dickinson). For cell cycle
analysis, exponentially growing passage-3 MEFs were labelled with
10 mM BrdU (Boehringer) at 37°C for 1 h and then mock-treated or
incubated with MMC (0.4 mg ml–1 for 1 h). After the chase period, cells
were fixed with 75% ethanol. Fixed cells were treated with 0.1 M HCl
containing 0.5% Triton X-100, followed by heating at 95°C and rapid
cooling to denature DNA. Cells were then incubated with florescein
isothiocyanate-conjugated anti-BrdU antibodies (Boehringer) and
counter stained with 2 mg ml–1 propidium iodine. For morphometric
measurement of the nuclear diameters, 3 mm-thick sections were
stained according to Mayer. Automated image analysis was carried out
using a Zeiss large research microscope fitted with a Bosch mono-
chromatic camera connected to a Kontron IBAS 2000 image analysis
system (Kontron Bildanalyse). A 6.3× objective was used, giving a mea-
surement field on liver section of 2.8 mm2, which was enlarged 100×
on the instrument monitor to give 306 pixels mm–1 of original image.
Reverse transcription PCR and dot-blot analysis
Total RNA was isolated from tissues by the LiCl/urea method [42]. The
RNA was used for preparing cDNA with ERCC1-specific primers.
Amplification was performed by 30 cycles of, consecutively, 2 min
denaturing at 95°C, 2 min annealing at around 50°C and 3 min exten-
sion at 70°C. Amplified DNA was spotted onto nitrocellulose filters and
hybridized to wild-type and mutant 32P-labelled primers. Mutation
detection was performed by RT-PCR on RNA isolated from day E13.5
MEFs. A 3′ mouse ERCC1 cDNA fragment was amplified by PCR with
oligonucleotides p1 (5′ CCTTATGCCCGGGCCTGGGCCCAC) and
p2 (5′ TTATTGTGACATGGGCTAGGTGGC). Amplified DNA was
spotted on nitrocellulose filters and hybridized with labelled oligonu-
cleotide probes p81 (specific for the ERCC1*292 mutation) and p228
(wild-type-specific; 5′ GGCACTTTGAGGAAGGGTTCGTGTAGTACT).
To assure that the samples were equally capable of undergoing amplifi-
cation of specific sequences by the PCR method, amplimers specific
for the mouse XPB gene — p108 (5′ CGACGCTGTGGCACCAT-
GAG) and p73 (5′ AACCTAGGACCCACGAAGG) — were added to
the cDNA mix and hybridized to a mouse XPB specific primer, p30
(5′ GCTGCCTGGATCCGTG).
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